BioSpace News Archive

Biotech Bay

Senti Bio Announces New Employment Inducement Grants - October 28, 2022

Senti Biosciences, Inc. announced that on October 27, 2022, the compensation committee of Senti Bio’s board of directors granted to 9 new employees stock options to purchase an aggregate of 200,200 shares of the Company’s common stock with a per share exercise price of $2.39.

October 28, 2022
·
2 min read
Business

Press Release: Continued strong growth in Q3 with key regulatory milestones achieved

Vaccines up 23.5% from strong Flu sales in the quarter, rebound of Travel vaccines and growth of Meningitis and PPH franchises.

October 28, 2022
·
3 min read
Vitrolife´s CEO has purchased shares

Vitrolife’s CEO Thomas Axelsson has acquired 12,000 shares worth 2,124,000 MSEK.

October 28, 2022
·
1 min read
SINOVAC to Showcase Products at CPHI Frankfurt

Sinovac Biotech Ltd. announced that the Company will participate in CPHI Frankfurt, one of the world’s largest pharmaceutical exhibitions, from 1st to 3rd of November, in Frankfurt, Germany.

October 28, 2022
·
2 min read
Drug Development

Marengo Therapeutics Presents Preclinical Proof-of Concept Data for STAR0602, a First-in-class Selective T cell Activator, at the 34th EORTC-NCI-AACR Symposium 2022

Marengo Therapeutics, Inc. presented the first preclinical proof-of-concept data on STAR0602, its novel TCR agonist antibody, during the 34th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics in Barcelona, Spain.

October 28, 2022
·
4 min read
Business

Appendix 4C - Q1 FY23 Quarterly Cash Flow Report

Alterity Therapeutics Limited, a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, releases its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending 30th September 2022.

October 28, 2022
·
6 min read
Pharm Country

Inmazeb™ (atoltivimab, maftivimab, and odesivimab-ebgn) Wins Prestigious 2022 Prix Galien USA Best Biotechnology Product Award

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Inmazeb™ (atoltivimab, maftivimab, and odesivimab-ebgn) has been recognized as the “Best Biotechnology Product” of 2022 by the Galien Foundation, which acknowledges extraordinary scientific innovations that improve the human condition.

October 28, 2022
·
13 min read
Genmab Announces Submissions of Regulatory Applications for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL) and Diffuse Large B-Cell Lymphoma (DLBCL)

Genmab has Submitted Biologics License Application (BLA) to U.S. Food and Drug Administration (FDA) for epcoritamab.

October 28, 2022
·
8 min read
Genetown

ImmunoGen Presents Retrospective Analysis of Extended Treatment Benefit from Multiple Trials of Mirvetuximab Soravtansine in Ovarian Cancer at ESGO

ImmunoGen, Inc. today announced findings from a retrospective pooled analysis of patients who achieved extended treatment benefit (ETB) with mirvetuximab soravtansine (mirvetuximab) monotherapy across three clinical trials in folate receptor alpha (FRα)–positive recurrent ovarian cancer.

October 28, 2022
·
6 min read
Nuevocor to Present Pre-clinical Data on its Gene Therapy Candidate for LMNA Dilated Cardiomyopathy at American Heart Association Scientific Sessions 2022

Nuevocor announced today that it will present new preclinical data on its adeno-associated virus (AAV) gene therapy for LMNA dilated cardiomyopathy at the American Heart Association (AHA) Scientific Sessions meeting on 5 – 7 November, 2022.

October 28, 2022
·
1 min read